Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Alzamend Neuro, Inc.

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital
From Alzamend Neuro, Inc.
Via GlobeNewswire
Tickers ALZN
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital
From Alzamend Neuro, Inc.
Via GlobeNewswire
Tickers ALZN
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital
From Alzamend Neuro, Inc.
Via GlobeNewswire
Tickers ALZN
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital
From Alzamend Neuro, Inc.
Via GlobeNewswire
Tickers ALZN
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital
From Alzamend Neuro, Inc.
Via GlobeNewswire
Tickers ALZN
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro to Present at the Sequire Investor Summit
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s Disease
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Reverse Stock Split
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Initial Closing of Private Placement
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Reverse Stock Split
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
From Alzamend Neuro, Inc.
Via Business Wire
Tickers ALZN
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.